For Biotech Founders & CEOs
Your first licensing deal sets the tone for everything that follows. Get it right.
Most biotech CEOs enter their first partnering conversation without knowing what comparable deals actually transacted for. Solidus gives you the data before you're at the table — so your board deck references real benchmarks, not assumptions.
What Solidus does for you
Before the first meeting
Run your asset through 21 engines. In 30 seconds, you know the upfront range, total deal value, milestone structure, and royalty tiers for your specific TA, modality, phase, and indication. Based on verified SEC 8-K filings — not press releases.
Before the board meeting
Generate a deal intelligence brief with comparable transactions, rNPV analysis, Monte Carlo distributions, and scenario comparisons (Bear/Base/Bull). Your board sees institutional-grade analysis, not a spreadsheet with three rows of comps.
Before you sign the term sheet
The Deal Structure Optimizer models all five deal structures (licensing, acquisition, co-development, option, collaboration) side by side. Know whether you're leaving money on the table with the structure you've been offered.
When the buyer says "this is market"
Pull the actual comp set. Filter by indication, modality, stage, territory. See exactly what "market" is — and where your asset falls relative to it. The Pharma Intent Score tells you how likely each buyer is to close.
The cost of not knowing
A Phase 2 oncology licensing deal has a median total deal value of $400M+. The difference between a well-benchmarked negotiation and an under-informed one is typically 10-20% of deal value. On a $400M deal, that's $40-80M left on the table.
Solidus Pro costs $299/month. A Deal Intelligence Brief is $2,500 for the full landscape. The math speaks for itself.